Probiotics and their medical use;Les probiotiques et leur place en médecine humaine

Journal des Anti-Infectieux

Volumn 16, Issue 2, 2014, Pages 33-43

  Butel, M J ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Diseases; Dysbiosis; Gut microbiota; Prevention; Probiotics; Safety

Indexed keywords

PROBIOTIC AGENT;

ALLERGIC DISEASE; ARTICLE; DIARRHEA; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSBIOSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; MENTAL DISEASE; METABOLIC DISORDER; OBESITY; SUSCEPTIBLE POPULATION;

EID: 84901588354     PISSN: 22106545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antinf.2014.01.010     Document Type: Article

References (109)

1. Sommer F., Backhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
2. Campeotto F., Waligora-Dupriet A.J., Doucet-Populaire F., Kalach N., Dupont C., Butel M.J. [Establishment of the intestinal microflora in neonates]. Gastroenterol Clin Biol 2007, 31:533-542.
3. FAO/WHO Health and nutritional properties of probiotics in food includion powder milk with live lactic acid bacteria 2001, S23-S33. [suppl.2, Argentina]. 30.
4. Roberfroid M., Gibson G.R., Hoyles L., McCartney A.L., Rastall R., Rowland I., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010, 104(Suppl.2):S1-S63.
5. Nyangale E.P., Mottram D.S., Gibson G.R. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 2012, 11:5573-5585.
6. Eckert C., Barbut F. [Clostridium-difficile-associated infections]. Med Sci (Paris) 2010, 26:153-158.
7. Okada H., Kuhn C., Feillet H., Bach J.F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010, 160:1-9.
8. Gerritsen J., Smidt H., Rijkers G.T., de Vos W.M. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 2011, 6:209-240.
9. Waligora-Dupriet A.J., Butel M.J. Microbiota and allergy: from dysbiosis to probiotics. Allergic diseases - Highlights in the clinic, mechanisms and treatment 2012, 413-434. Intech, Rijeka. C. Pereira (Ed.).
10. Dahlqvist G., Piessevaux H. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg 2011, 74:375-380.
11. Marchesi J.R., Dutilh B.E., Hall N., Peters W.H., Roelofs R., Boleij A., et al. Towards the human colorectal cancer microbiome. PLoS ONE 2011, 6:e20447.
12. Tilg H., Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011, 121:2126-2132.
13. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
14. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
15. Sanz Y., Rastmanesh R., Agostonic C. Understanding the role of gut microbes and probiotics in obesity: how far are we?. Pharmacol Res 2013, 69:144-155.
16. Turnbaugh P.J., Backhed F., Fulton L., Gordon J.I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3:213-223.
17. Wu X., Ma C., Han L., Nawaz M., Gao F., Zhang X., et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010, 61:69-78.
18. Larsen N., Vogensen F.K., van den Berg F.W., Nielsen D.S., Andreasen A.S., Pedersen B.K., et al. Gut microbiota in human adults with type 2diabetes differs from non-diabetic adults. PLoS ONE 2010, 5:e9085.
19. Ebel B., Lemetais G., Beney L., Cachon R., Sokol H., Langella P., et al. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr 2014, 54:175-189.
20. Atkinson M.A., Chervonsky A. Does the gut microbiota have a role in type 1diabetes? Early evidence from humans and animal models of the disease. Diabetologia 2012, 55:2868-2877.
21. Montiel-Castro A.J., Gonzalez-Cervantes R.M., Bravo-Ruiseco G., Pacheco-Lopez G. The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci 2013, 7:70.
22. Bravo J.A., Julio-Pieper M., Forsythe P., Kunze W., Dinan T.G., Bienenstock J., et al. Communication between gastrointestinal bacteria and the nervous system. Curr Opin Pharmacol 2012, 12:667-672.
23. Louis P. Does the human gut microbiota contribute to the etiology of autism spectrum disorders?. Dig Dis Sci 2012, 57:1987-1989.
24. Finegold S.M., Downes J., Summanen P.H. Microbiology of regressive autism. Anaerobe 2012, 18:260-262.
25. Metchnikoff E. The prolongation of life: optimistic studies 1908, G.P. Putnam's Sons ed, New York and London.
26. Guidelines for the evaluation of probiotics in food 2002, FAO/WHO Working group, [London].
27. Liong M.T. Safety of probiotics: translocation and infection. Nutr Rev 2008, 66:192-202.
28. Vahabnezhad E., Mochon A.B., Wozniak L.J., Ziring D.A. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 2013, 47:437-439.
29. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl.2):S104-S111.
30. Kunz A.N., Noel J.M., Fairchok M.P. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004, 38:457-458.
31. Land M.H., Rouster-Stevens K., Woods C.R., Cannon M.L., Cnota J., Shetty A.K. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
32. Panel on biological hazards EFSA (BIOHAZ) Scientific opinion on the maintenance of the list of QPS biological agents intentionnally added to food and feed (2012update). EFSA J 2012, 10:3020-3084.
33. Jenke A., Ruf E.M., Hoppe T., Heldmann M., Wirth S. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed 2012, 97:F217-F218.
34. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van G.H., Timmerman H.M., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
35. Hennequin C., Kauffmann-Lacroix C., Jobert A., Viard J.P., Ricour C., Jacquemin J.L., et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000, 19:16-20.
36. Connolly E., Abrahamsson T., Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Pediatr Gastroenterol Nutr 2005, 41:489-492.
37. EFSA Scientific opinion of the panel on biological hazards on a request from EFSA on the maintenance of the QPS list of microorganisms intentionally added to food or feed. EFSA J 2008, 923:1-48.
38. Verraes C., Van B.S., Van M.E., Van C.E., Butaye P., Catry B., et al. Antimicrobial resistance in the food chain: a review. Int J Environ Res Public Health 2013, 10:2643-2669.
39. Aires J., Doucet-Populaire F., Butel M.J. Tetracycline resistance mediated by tet(W), tet(M), and tet(O) genes of Bifidobacterium isolates from humans. Appl Environ Microbiol 2007, 73:2751-2754.
40. Aires J., Thouverez M., Doucet-Populaire F., Butel M.J. Consecutive human bifidobacteria isolates and acquired tet genes. Int J Antimicrob Agents 2008.
41. van Reenen C.A., Dicks L.M. Horizontal gene transfer amongst probiotic lactic acid bacteria and other intestinal microbiota: what are the possibilities? A review. Arch Microbiol 2011, 193:157-168.
42. Kazimierczak K.A., Flint H.J., Scott K.P. Comparative analysis of sequences flanking tet(W) resistance genes in multiple species of gut bacteria. Antimicrob Agents Chemother 2006, 50:2632-2639.
43. Moubareck C., Bourgeois N., Courvalin P., Doucet-Populaire F. Multiple antibiotic resistance gene transfer from animal to human enterococci in the digestive tract of gnotobiotic mice. Antimicrob Agents Chemother 2003, 47:2993-2996.
44. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, CD480030.
45. Huang J.S., Bousvaros A., Lee J.W., Diaz A., Davidson E.J. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002, 47:2625-2634.
46. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33(Suppl.2):S17-S25.
47. Salari P., Nikfar S., Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012, 11:3-14.
48. Bernaola A.G., Bada Mancilla C.A., Carreazo Pariasca N.Y., Rojas Galarza R.A. Probiotics for treating persistent diarrhoea in children. Cochrane Database Syst Rev 2010, CD010074.
49. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
50. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, CD004827.
51. Goldenberg J.Z., Ma S.S., Saxton J.D., Martzen M.R., Vandvik P.O., Thorlund K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013, 5:CD006095.
52. Johnston B.C., Ma S.S., Goldenberg J.Z., Thorlund K., Vandvik P.O., Loeb M., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012, 157:878-888.
53. Shim J.O. Gut microbiota in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2013, 16:17-21.
54. Seksik P. [Gut microbiota and IBD]. Gastroenterol Clin Biol 2010, 34(Suppl.1):S44-S51.
55. Khan K.J., Ullman T.A., Ford A.C., Abreu M.T., Abadir A., Marshall J.K., et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106:661-673.
56. Jonkers D., Penders J., Masclee A., Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012, 72:803-823.
57. Naidoo K., Gordon M., Fagbemi A.O., Thomas A.G., Akobeng A.K. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011, CD007443.
58. Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012, 7:e34938.
59. Mack D.R. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011, 3:245-264.
60. Nagalingam N.A., Lynch S.V. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012, 18:968-984.
61. Ohman L., Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013, 15:323.
62. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Brandt L.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010, 59:325-332.
63. Dai C., Zheng C.Q., Jiang M., Ma X.Y., Jiang L.J. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013, 19:5973-5980.
64. McKenzie Y.A., Alder A., Anderson W., Wills A., Goddard L., Gulia P., et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012, 25:260-274.
65. Quigley E.M. Gut microbiota and the role of probiotics in therapy. Curr Opin Pharmacol 2011, 11:593-603.
66. Zhang M.M., Cheng J.Q., Lu Y.R., Yi Z.H., Yang P., Wu X.T. Use of pre-, pro- and synbiotics in patients with acute pancreatitis: a meta-analysis. World J Gastroenterol 2010, 16:3970-3978.
67. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007, 25:155-168.
68. Wilhelm S.M., Johnson J.L., Kale-Pradhan P.B. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011, 45:960-966.
69. Lionetti E., Francavilla R., Castellazzi A.M., Arrigo T., Labo E., Leonardi S., et al. Probiotics and Helicobacter pylori infection in children. J Biol Regul Homeost Agents 2012, 26:S69-S76.
70. Serban E.D. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett 2013.
71. Kim H.J., Kim H.Y., Lee S.Y., Seo J.H., Lee E., Hong S.J. Clinical efficacy and mechanism of probiotics in allergic diseases. Korean J Pediatr 2013, 56:369-376.
72. Castellazzi A.M., Valsecchi C., Caimmi S., Licari A., Marseglia A., Leoni M.C., et al. Probiotics and food allergy. Ital J Pediatr 2013, 39:47.
73. Kuitunen M. Probiotics and prebiotics in preventing food allergy and eczema. Curr Opin Allergy Clin Immunol 2013, 13:280-286.
74. Kuitunen M., Kukkonen K., Juntunen-Backman K., Korpela R., Poussa T., Tuure T., et al. Probiotics prevent IgE-associated allergy until age 5years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol 2009, 123:335-341.
75. Shen J., Obin M.S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013, 34:39-58.
76. Vrieze A., Van N.E., Holleman F., Salojarvi J., Kootte R.S., Bartelsman J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916.
77. Stapleton A.E., Au-Yeung M., Hooton T.M., Fredricks D.N., Roberts P.L., Czaja C.A., et al. Randomized, placebo-controlled phase 2trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011, 52:1212-1217.
78. Grin P.M., Kowalewska P.M., Alhazzan W., Fox-Robichaud A.E. Lactobacillus for preventing recurrent urinary tract infections in woman: meta-analysis. Can J Urol 2013, 20:6607-6614.
79. MacPhee R.A., Hummelen R., Bisanz J.E., Miller W.L., Reid G. Probiotic strategies for the treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother 2010, 11:2985-2995.
80. Hao Q., Lu Z., Dong B.R., Huang C.Q., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011, CD006895.
81. Popova M., Molimard P., Courau S., Crociani J., Dufour C., Le V.F., et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol 2012, 113:1305-1318.
82. Siempos I.I., Ntaidou T.K., Falagas M.E. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:954-962.
83. Gu W.J., Wei C.Y., Yin R.X. Lack of efficacy of probiotics in preventing ventilator-associated pneumonia probiotics for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. Chest 2012, 142:859-868.
84. Dinan T.G., Stanton C., Cryan J.F. Psychobiotics: a novel class of psychotropic. Biol Psychiatry 2013, 74:720-726.
85. Messaoudi M., Violle N., Bisson J.F., Desor D., Javelot H., Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2011, 2:256-261.
86. Benton D., Williams C., Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 2007, 61:355-361.
87. Rao A.V., Bested A.C., Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009, 1:6.
88. Gaggia F., Mattarelli P., Biavati B. Probiotics and prebiotics in animal feeding for safe food production. Int J Food Microbiol 2010, 141(Suppl.1):S15-S28.
89. Moubareck C., Dantier R., Butel M.J., Doucet-Populaire F. Influence of Bifidobacterium on the transfert of beta-lactam resistance between enterobacteria. Anaerobe 2005, 11:50.
90. Vidal M., Forestier C., Charbonnel N., Henard S., Rabaud C., Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol 2010, 48:2595-2598.
91. de Regt M.J., Willems R.J., Hene R.J., Siersema P.D., Verhaar H.J., Hopmans T.E., et al. Effects of probiotics on acquisition and spread of multiresistant enterococci. Antimicrob Agents Chemother 2010, 54:2801-2805.
92. Laubereau B., Filipiak-Pittroff B., von B.A., Grubl A., Reinhardt D., Wichmann H.E., et al. Caesarean section and gastrointestinal symptoms, atopic dermatitis, and sensitisation during the first year of life. Arch Dis Child 2004, 89:993-997.
93. Agosti M., Vegni C., Gangi S., Benedetti V., Marini A. Allergic manifestations in very low-birthweight infants: a 6-year follow-up. Acta Paediatr Suppl 2003, 91:44-47.
94. Huh S.Y., Rifas-Shiman S.L., Zera C.A., Edwards J.W., Oken E., Weiss S.T., et al. Delivery by caesarean section and risk of obesity in preschool age children: a prospective cohort study. Arch Dis Child 2012.
95. Schippa S., Conte M.P., Borrelli O., Iebba V., Aleandri M., Seganti L., et al. Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:661-672.
96. Finegold S.M., Molitoris D., Song Y., Liu C., Vaisanen M.L., Bolte E., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35:S6-S16.
97. Cardwell C.R., Stene L.C., Joner G., Cinek O., Svensson J., Goldacre M.J., et al. Caesarean section is associated with an increased risk of childhood-onset type 1diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008, 51:726-735.
98. Thomas D.W., Greer F.R. Probiotics and prebiotics in pediatrics. Pediatrics 2010, 126:1217-1231.
99. Butel M.J., Waligora-Dupriet A.J., Aires J. Usefulness of probiotics for neonates. Probiotics 2012, 457-480. Intech. E.C. Rigobela (Ed.).
100. Mugambi M.N., Musekiwa A., Lombard M., Young T., Blaauw R. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J 2012, 11:81.
101. Braegger C., Chmielewska A., Decsi T., Kolacek S., Mihatsch W., Moreno L., et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2011, 52:238-250.
102. Mugambi M.N., Musekiwa A., Lombard M., Young T., Blaauw R. Probiotics, prebiotics infant formula use in preterm or low birth weight infants: a systematic review. Nutr J 2012, 11:58.
103. Alfaleh K., Anabrees J., Bassler D., Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, CD005496.
104. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
105. Kassam Z., Lee C.H., Yuan Y., Hunt R.H. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013, 108:500-508.
106. Van N.E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
107. Borody T.J., Brandt L.J., Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014, 30:97-105.
108. Lepage P., Leclerc M.C., Joossens M., Mondot S., Blottiere H.M., Raes J., et al. A metagenomic insight into our gut's microbiome. Gut 2013, 62:146-158.
109. Lamendella R., VerBerkmoes N., Jansson J.K. 'Omics' of the mammalian gut--new insights into function. Curr Opin Biotechnol 2012, 23:491-500.